Vulvoplasty¶
External feminizing genitoplasty without a vaginal canal. Also called zero-depth, minimal-depth, shallow-depth, or cosmetic vulvoplasty — names for the same procedure, which builds an externally typical vulva (clitoris, clitoral hood, labia majora, labia minora, feminine urethral meatus) with no vaginal canal, or only a 2–3 cm cosmetic dimple at the introitus that is not designed for penetration.
The externals are essentially indistinguishable from a full Penile-Inversion Vaginoplasty by the same surgeon, and the dorsal-pedicle neoclitoris is built the same way. What is omitted is the canal: no perineal dissection between bladder and rectum, no skin or peritoneal lining graft, no postoperative dilation regimen.
This is a distinct procedural choice, not a "lesser" or "easier" version of vaginoplasty. WPATH SOC-8 and the major North American programs frame it that way explicitly, because patients otherwise read "no canal" as "incomplete" — which it is not, for the patients who choose it.
Literature is sparse
The vulvoplasty literature is substantially thinner than the vaginoplasty literature. Most published series are mixed-cohort papers where vulvoplasty patients are a small subset (5–15% of practice). Dedicated series are rare, small (typically n=20–60), and almost entirely retrospective single-surgeon. Numbers on this page are extrapolated from mixed cohorts or single-center series — read ranges with that caveat in mind.
Who actually chooses vulvoplasty¶
Patients who don't want penetrative-receptive function. The largest single group across published cohorts. Jiang et al. 2018 (UCSF, one of the few dedicated vulvoplasty-choice studies) reported that ~80% of their patients cited "no desire for vaginal intercourse" as the primary reason, with avoidance of dilation a strong secondary. Reasons span sexual orientation, asexuality, age and partner status, prior negative experiences with penetration, or simply not valuing that function relative to the externals.
Patients with medical contraindications to canal creation. The original textbook indication:
- Prior pelvic radiation (e.g. prostate or rectal cancer) — fibrosis distorts the rectoprostatic plane and dramatically elevates rectal injury and fistula risk.
- Prior abdominoperineal surgery with significant scarring.
- Severe obesity (BMI thresholds vary; commonly >35 or >40 as a relative contraindication to canal vaginoplasty).
- Active smoking the patient is unwilling or unable to stop — canal creation depends heavily on flap perfusion.
- Advanced age or cardiopulmonary comorbidity where reducing OR time (typically 2–3 hours less than full vaginoplasty) meaningfully changes the risk calculus.
- Unfavorable pelvic anatomy — very narrow outlets or congenital variants.
Patients unwilling to commit to lifelong dilation. Penile-inversion and peritoneal vaginoplasty require multiple-times-daily dilation for the first 3 months, tapering to once daily for ~9 more months, then 2–3 times per week indefinitely for canal patency. Real-world adherence drops over time, and stenosis from missed dilation is a common cause of revision. Patients whose work, caregiving load, disability, chronic pain, or PTSD around insertional contact makes a sustained dilation regimen impractical — or who simply assess their willingness honestly — sometimes choose vulvoplasty specifically to remove that burden. Surgeons increasingly treat this as a legitimate primary indication, not a fallback. See Recovery & Dilation for what canal-vaginoplasty dilation actually looks like.
Patients prioritizing recovery and reduced morbidity. Shorter operative time (3–4 hours vs. 4–6+), shorter inpatient stay (2–3 days vs. 4–6), no canal pack, faster return to activities. The tradeoff is real and patients increasingly choose it openly.
A small but growing fifth group: staged "delayed two-stage" patients who plan vulvoplasty first and a canal addition later, usually when they want orchiectomy and external feminization sooner than full vaginoplasty wait times allow. Conversion is feasible but not the typical path — see below.
Surgical mechanics¶
The external work is identical to the external portion of a penile-inversion vaginoplasty. The single difference is that the perineal canal dissection is omitted.
- Orchiectomy first if not already done.
- Penile disassembly. Shaft skin degloved as a tube; corpora cavernosa resected at the proximal crura. Dorsal neurovascular bundle preserved meticulously — the same dissection that supplies neoclitoral sensation.
- Neoclitoris. Glans wedge on its dorsal pedicle, ~1–1.5 cm transverse, inset at the apex of the labia minora; hood from dorsal preputial or shaft skin. Sensory outcomes depend on the same nerve preservation as in full vaginoplasty and are not expected to differ — worth emphasizing because patients sometimes assume the smaller procedure means smaller sensation.
- Urethroplasty. Bulbar urethra resected back to a feminine angle; spongy tissue partially preserved as urethral mucosa for the meatus. Some surgeons use spatulated urethral mucosa to line a 2–3 cm cosmetic vestibular dimple (the "minimal-depth" variant).
- Labia majora. Scrotal skin split, de-haired (preoperatively — see Pre-Op Hair Removal), rotated; midline raphe becomes the posterior commissure.
- Labia minora and introitus. Shaft and preputial tissue flanking meatus and neoclitoris. Introitus closed flat (zero-depth) or tacked into a 2–3 cm blind pouch (minimal-depth). In zero-depth closure, the perineal body is reinforced by approximating bulbospongiosus and perineal fascia.
What is not done: no rectoprostatic dissection, no canal, no skin or peritoneal lining graft, no canal packing, no dilation regimen.
Sensation and aesthetic outcomes¶
For the components that exist, vulvoplasty outcomes are not meaningfully different from full vaginoplasty by the same surgeon: the neoclitoris is built from the same tissue with the same pedicle, the labia from the same flaps. Published cohorts using validated instruments (FSFI) report orgasmic capacity in the 70–85% range, overlapping the vaginoplasty literature's 70–90%. Jiang 2018 reported high satisfaction on aesthetic and functional dimensions excluding penetrative function — the appropriate comparison.
What vulvoplasty does not provide, by design, is penetrative-receptive function. Patients should model this absence explicitly. For some it is a non-issue or an active preference; for others, retrospective regret centers on this single point and predicts later interest in conversion.
Conversion to full vaginoplasty later¶
Technically feasible at most experienced centers, but tissue planes are less favorable than in primary vaginoplasty. The mechanics: scrotal and penile shaft skin that would have lined a primary canal has been spent on the labia; the reconstructed perineal body scars the rectoprostatic plane; the dorsal pedicle to the neoclitoris must be preserved through any further dissection.
Conversion is therefore most often done with a non-genital-skin canal lining — peritoneal flap (Davydov-style), sigmoid segment, or buccal mucosa graft. Most surgeons offering primary vulvoplasty discuss this up front: converting later will likely mean peritoneal or intestinal vaginoplasty, not penile-inversion, with that complication profile (intra-abdominal access, longer recovery, intestinal- or peritoneal-specific risks). Published conversion rates are low — most series report <10% requesting conversion at 2–5 year follow-up — but follow-up is short and the literature is sparse.
The practical implication: choose vulvoplasty because you want vulvoplasty, not as a low-commitment "trial" you expect to upgrade. If uncertain, several surgeons counsel choosing primary penile-inversion or peritoneal vaginoplasty instead, since the canal is easier to create de novo than to add later. See Candidacy & Timing.
Recovery¶
Recovery is meaningfully faster than full vaginoplasty across the board.
| Phase | Vulvoplasty | Penile-inversion (comparison) |
|---|---|---|
| Hospital stay | 1–3 days | 3–5 days (longer for peritoneal) |
| Foley catheter | 5–10 days | 5–10 days |
| Desk/remote work | 3–4 weeks | 6–8 weeks |
| Full activity | 8–12 weeks (cycling may need longer) | 12+ weeks |
| Sexual activity | ~8–12 weeks (clitoral/external) | ~12 weeks; penetrative deferred further |
| Dilation | None | 3×/day → daily → 2–3×/week indefinitely |
| Final aesthetic | 6–12 months | 6–12 months |
The dilation row is the recovery-defining difference: no 3–4×/day sessions for the first 3 months, no indefinite maintenance, no stenosis risk from missed sessions. Wound care is local hygiene with gentle irrigation, sitz baths once incisions seal, and topical estrogen cream sometimes prescribed to support urethral and labial mucosal healing.
Complications and risks¶
The complication profile is the external-work subset of the vaginoplasty profile: same risks for the structures that are built, with canal-related complications eliminated.
| Complication | Reported rate | Notes |
|---|---|---|
| Hematoma | 5–10% | Occasionally requires operative drainage. |
| Wound dehiscence | 5–15% | Labial or perineal incisions; usually managed conservatively. |
| Urinary stream issues | 10–20% (some series) | Spraying, deviation, splitting; often improves as edema resolves; persistent cases may revise. |
| Meatal stenosis | 2–5% | Occasional dilation or revision. |
| UTI in first month | 5–15% | |
| Transient sensation change | Common | Hyper- or hyposensitivity of neoclitoris and labia; most resolve over 6–12 months. |
| Permanent clitoral sensory loss | <1–2% | Only if dorsal pedicle is compromised; rare in experienced hands. |
| Minor aesthetic revision | ~10–20% | Labial asymmetry, clitoral hood positioning, scrotal-to-labial bulk, scar visibility. |
| Granulation tissue | Common | Suture lines; treated with silver nitrate or topical steroids. |
Eliminated by omitting the canal: rectovaginal fistula (0.5–5% in vaginoplasty series), vaginal stenosis, canal prolapse, intra-abdominal complications specific to peritoneal or intestinal lining, and dilation-related trauma/granulation/infection.
Published vulvoplasty cohorts report total complication rates ~30–40% lower than matched vaginoplasty cohorts from the same surgeons, driven almost entirely by the absence of canal-specific complications.
Smoking, BMI >35, poorly controlled diabetes, and incomplete preoperative scrotal hair removal are the modifiable risk factors — identical to the vaginoplasty profile.
Cost and insurance¶
US out-of-pocket pricing roughly \(15,000–\)40,000 for surgeon, facility, and anesthesia combined — below penile-inversion vaginoplasty (\(25,000–60,000) and well below peritoneal (\)35,000–80,000+). International pricing (Thailand, Mexico) is lower, but vulvoplasty is rarely a primary destination procedure since most international centers focus on full-depth work.
US insurance coverage has expanded substantially since 2014. Vulvoplasty is generally covered by the same plans that cover vaginoplasty — Medicare since 2014, most state Medicaid programs that cover transition care, and most major commercial insurers under WPATH-aligned criteria. Some plans require explicit pre-authorization (often CPT 57335 or unlisted female genital codes plus orchiectomy and urethroplasty codes). A handful have historically refused vulvoplasty while approving vaginoplasty on the (incorrect) reasoning that it is "incomplete" — appeals citing WPATH SOC-8's explicit recognition of vulvoplasty as a primary indicated procedure have been broadly successful.
What the literature does not yet establish¶
Long-term (10+ year) outcomes are scarce; regret and conversion rates beyond 5 years are not well characterized; the FSFI used in most sexual-function reports was designed for cis women and several items (lubrication, penetrative satisfaction) are non-applicable, distorting aggregate scores; no comparative literature exists on the dimple-vs-flat closure decision.
When choosing a surgeon, ask specifically about vulvoplasty case volume — not just total bottom-surgery volume — since technical decisions for the externals differ subtly when no canal is created (how the perineal body is reinforced, how urethral length is set without a canal-introitus relationship).
Sources¶
The vulvoplasty-specific literature is sparse — fewer than ten dedicated outcome studies, with the largest single-surgeon cohorts in the n=40–80 range. Most numbers in this page are extrapolated from mixed cohorts where vulvoplasty patients were a subset.
Dedicated vulvoplasty literature¶
- Jiang D, Witten J, Berli J, Dugi D (2018). Does Depth Matter? Factors Affecting Choice of Vulvoplasty Over Vaginoplasty as Gender-Affirming Genital Surgery for Transgender Women. Journal of Sexual Medicine 15(6):902–906. The canonical dedicated vulvoplasty-choice study; UCSF cohort.
- Jiang et al., 2019, Obstetrics & Gynecology. (OHSU/Dugi pelvic-floor PT program with a vulvoplasty subgroup.)
Standards and background¶
- Coleman et al. (2022). Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health. (WPATH SOC-8 — explicit recognition of vulvoplasty as a primary indicated procedure.)
- Hadj-Moussa, Ohl, Kuzon, 2018, Sexual Medicine Reviews; Horbach et al., 2015, Journal of Sexual Medicine (vaginoplasty complication denominators).
- Schardein, Zhao, Nikolavsky, 2019, Urologic Clinics of North America. (Separates canal-related from external complications.)
- Salgado et al., 2018, BioMed Research International. (Staged vulvoplasty-to-canal conversion considerations.)
- van der Sluis et al., 2016, Plastic and Reconstructive Surgery. (Conversion-pathway tissue-availability discussion.)
- Milrod, Monto, Karasic, 2019, Journal of Sexual Medicine.
Patient-education resources¶
Penn Medicine Center for Transgender Health, OHSU Transgender Health Program, Mount Sinai CTMS, Crane Center, and Marci Bowers's public lectures and patient materials on minimal- and zero-depth vaginoplasty (multiple WPATH symposium presentations, 2017–2023).